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Aims: To review the medicines optimisation activities of the All Wales Medicines
Strategy Group (AWMSG), a committee established in 2002 to advise the Welsh
Government on “all matters related to prescribing”. Although AWMSG conducts
other activities (e.g., health technology appraisal for medicines), we focus here on its
role in advising on medicines optimisation.
Methods: Prescribing indicators have been used in Wales to measure change,
together with data on volumes and costs of medicines dispensed. A range of
improvement strategies have been categorised under the “four Es”, namely
educational initiatives, economic incentives, “engineering” and “enforcement”.
Results: AWMSG has helped health professionals in NHS Wales to reduce harm and
waste, and to reduce inappropriate local or regional duplication and variation. Specific
initiatives include the achievement of major cost savings by supporting increased
generic prescribing and an “invest to save” approach related to prescribing of
hypnotics and tranquillisers, non-steroidal anti-inflammatory drugs (NSAIDs) and
proton pump inhibitors. AWMSG also successfully commissioned the introduction of
a single national in-patient medication chart for Wales in 2004. Ongoing priorities
include a focus on reducing prescribing of certain medicines deemed “low value for
prescribing” and on optimising the use of biosimilar medicines.
Conclusions: Since 2002, AWMSG has acted as a national medicines optimisation
committee in Wales. From the outset, pharmacists and clinical pharmacologists have
collaborated closely and shared their complementary expertise to make a much
greater contribution to the safe, effective and cost-effective use of medicines than
either group could have achieved by working separately.
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1 | INTRODUCTION
1.1 | History, structure and roles of AWMSG
In 1998, responsibility for the running of the NHS in Wales was trans-
ferred to the Welsh Government as part of the political process of
devolution. A Task and Finish Group on Prescribing was established
(chaired by Dr Norman Mills, a hospital Chief Executive and public
health physician), and in 2001 it recommended that there should be
an all-Wales committee to advise the Welsh Government on medi-
cines issues.1 The All Wales Medicines Strategy Group (AWMSG) was
then established in 2002 as a statutory advisory Welsh Assembly-
sponsored public body under the 1977 NHS Act, and it met for the
first time in October 2002 in Wrexham. The new group's initial roles
were to advise the Welsh Government on “all matters related to pre-
scribing” and to conduct health technology appraisal (HTA) of certain
high-cost medicines in Wales. It is supported professionally in its med-
icines optimisation and HTA activities by pharmacists, pharmacy tech-
nicians, clinical pharmacologists, life scientists and administrative staff
who now work within the All Wales Therapeutics and Toxicology
Centre (AWTTC), formerly the Welsh Medicines Partnership which
receives funding from the Welsh Government for these activities.2
AWMSG was also tasked with advising the Welsh Government
on future developments in healthcare and on the development of a
prescribing strategy for Wales. Members of AWMSG include health
professionals, senior managers (e.g., Finance Director) drawn from the
seven health boards (HBs) and one trust across Wales, a health econo-
mist, lay representative and an Association of British Pharmaceutical
Industries (ABPI) member representing the UK pharmaceutical indus-
tries. Health professional representation includes a Medical Director,
clinical pharmacologist, consultant in public health medicine, general
practitioner with a prescribing lead role, hospital consultant, managed
sector hospital and primary care pharmacist, pharmacist with an inter-
est in public health, senior nurse, and a member from the other pro-
fessions eligible to prescribe.
AWMSG published guidance for partnership working between
NHS organisations, primary care contractors, the pharmaceutical
industry and allied commercial sector organisations in Wales in 2004,3
and since 2006, the ABPI has provided one of the 16 voting members
on AWMSG. From the first meeting, the Group has met (normally
10 times per year in venues around Wales) in public to ensure trans-
parency of the processes used to formulate advice. The minutes of
the AWMSG meetings are in the public domain and available on the
AWMSG website.
AWMSG is supported in its medicines optimisation consider-
ations by a sub-group, the All Wales Prescribing Advisory Group
(AWPAG) which has broad geographical/multi-professional represen-
tation from the HBs as well as lay representation, in the same manner
as AWMSG. AWPAG meets quarterly and develops documents (nor-
mally after wide all Wales consultation) for further consideration and
final sign-off by AWMSG. Another sub-group, the New Medicines
Group contributes to AWMSG's health technology appraisal (HTA)
processes.4
1.2 | Demography of health and healthcare in
Wales
Wales shares a land border with England but is very much smaller,
with a population of 3.152 million (mid-year 2019) compared with
56.286 million for its immediate neighbour.5 The gross domestic prod-
uct (GDP) per head in Wales in 2018 was £23 866 compared with
£32 875 in England. The only English region with a lower GDP than
Wales was the North-East of England (at £23 569).6 In 2011, 23% of
people living in Wales had an activity-limiting health problem com-
pared with 17% in England (22% in the North-East of England).7
Because of the demographic similarities between the North-East of
England and Wales, it has sometimes been used as a comparator for
Wales in relation to prescribing.1,8
In 2002 there were 22 local health boards (LHBs) across Wales,
but in 2009 this was reduced to seven larger health boards (HBs), and
one Trust focusing on cancer services (Velindre NHS Trust). The pre-
sent configuration of HBs in Wales in 2020 is shown in Figure 1. The
rate of prescribing per resident of Wales has been historically consis-
tently greater than in England, with 26% more items prescribed per
What is already know about this subject
• Regional Medicines Optimisation Committees (RMOCs)
were established in England in 2018 to encourage good
prescribing practice and to highlight unwarranted varia-
tion in their regions and more widely in the NHS in
England.
• In 2002, Welsh Government established the All Wales
Medicines Strategy Group (AWMSG) to conduct health
technology appraisals of certain new medicines, and to
advise on medicines optimisation issues in the NHS in
Wales.
What this study adds
• It demonstrates that AWMSG has been able to promote
prudent prescribing and help to reduce harm, waste, and
inappropriate variation over a sustained period of almost
two decades. Examples include the introduction of a sin-
gle national in-patient medication chart (2004), and a suc-
cessful “invest to save” prescribing initiative (beginning in
2009).
• It highlights how pharmacists and clinical pharmacolo-
gists, working together on medicines optimisation issues
can make a greater contribution to the safe, effective,
and cost-effective use of medicines than either group
could have achieved by working separately.
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head in 1999.1 The prescribing rate also then correlated positively
with deprivation, so there were 15 items prescribed per person per
year in Merthyr Tydfil in 1999/2000 compared with less than 10 in
Cardiff and Powys.1 In this paper, we describe the Group's medicines
optimisation role and related activities over the last 18 years. The
HTA activities of AWMSG have been described in detail elsewhere.4
2 | METHODS
2.1 | Driving change: The 4 E's of medicines
optimisation
In the context of outpatient medication safety, Budnitz and Layde
identified three main improvement strategies, categorised under the
headings of education, engineering and enforcement.9 These (with the
addition of a fourth, economic) were subsequently applied to the ratio-
nal use of medicines by Krska and Godman.10 Educational activities
include the production and dissemination of prescribing guidance,
including intensive strategies such as educational outreach. Engineer-
ing activities can include organisational or managerial interventions,
such as application of prescribing and quality targets (e.g., national
prescribing indicators). They may involve the introduction of
standardised processes (e.g., standardised prescribing charts) but may
also include the use of software solutions such as decision support
systems, or processes to optimise the managed entry of new
medicines.
Economic interventions include financial and non-financial incen-
tives/disincentives to prescribing (including co-payments for patients).
Enforcement in health systems internationally may include legally
enforced regulations, restrictions in prescribing or dispensing certain
medicines (e.g., by applying prior authorisation schemes), compulsory
generic substitution, or compulsory prescribing by international non-
proprietary (INN) name.11
An advisory committee like AWMSG does not have enforcement
powers but it can advise the Welsh Government in relation to guid-
ance contained in relevant Welsh Health Circulars (WHCs) in NHS
Wales (see Table 1). A range of educational, economic and engineer-
ing activities are often required to be used over a sustained period
and some of the policies and actions used in Wales to effect change
over the last 18 years are outlined in this article and listed in Table 1.
2.2 | Measuring change: Prescribing data and
national prescribing indicators (NPIs)
Primary care prescribing data was extracted from NHS Wales Shared
Services Partnership's Comparative Analysis System for Prescribing
Audit (CASPA) in Wales and from NHS Business Services Authority's
Electronic Prescribing Analysis and Cost Tool (ePACT) in England.
F IGURE 1 Health boards (HBs) in Wales from 1 April 2019
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Hospital prescribing data was extracted from the NHS Wales Infor-
matics Service's Medusa prescribing system.
Prescribing indicators are quantitative measures of prescribing,
which allow benchmarking comparisons between prescribers, regions
and countries and changes in the prescribing patterns. They can be
used (with associated targets) to encourage peer pressure to influence
prescribing behaviour and to inform prescribing incentive schemes,
but do not indicate reasons for any changes observed.10 For some
NPIs in Wales, AWMSG has agreed a “threshold” rate of performance,
which is not a target as such but indicates a nationally agreed aspira-
tional performance level.
Prescribing indicators were initially chosen by AWMSG based on
published indicators that had been selected to have face validity for
measuring quality or cost minimisation, using existing prescribing anal-
ysis and cost data. Twelve such indicators had previously been rated
as valid by leading prescribing advisers in England via a two-stage
Delphi process,12 and AWMSG initially based the national indicators
in Wales on one of the five related to cost minimisation (generic
prescribing rate [%]) and two of the seven relating to quality and
safety (antibiotic items and hypnotics/anxiolytic items).
The NPIs are reviewed annually after full consultation and added
to, modified or replaced when deemed appropriate. Information
concerning their rationale, the associated targets and the supporting
evidence are sent to HBs regularly together with feedback on perfor-
mance and associated learning resources. Several of the NPIs have
also been included in relevant prescribing incentive schemes in Wales.
Similar NPIs are used in each of the other three countries of the UK,
and NPIs have been developed internationally, including by the World
Health Organization.
2.3 | Strategies for change
From 2003 until 2008, AWMSG worked to implement as many as
possible of the 96 recommendations contained in the 2001 Task and
Finish Report on Prescribing.1 Thereafter, AWMSG has published its
own prescribing strategies in 2008, 2013 and 2018. Each strategy
was agreed after wide consultation across Wales. The strategy docu-
ments and the annual reports of AWMSG contain further details of
the medicine's optimisation activities implemented in Wales since
2002. These documents are all available on the AWMSG website at
http://www.awmsg.org/
3 | RESULTS
3.1 | Impact of the prescribing indicators
The first national prescribing indicator (NPI) agreed by AWMSG was
to further promote generic prescribing. A report from the Office of
Fair Trading in 2007 noted that the policy across the UK to encourage
GPs to prescribe generically (by approved name) was based on both
safety and cost issues.13 The report stated that medication errors may
be reduced if all doctors use the same (approved) name for a medi-
cine, some of which may have a variety of brand names. In relation to
cost, generic equivalents which appear in the market when the patent
for a branded medicine expires are usually less expensive for the NHS
to procure. However, a prescription must be written using the medi-
cine's approved name for the pharmacist to be allowed to dispense it
generically.13
In 2001, the average rate of generic prescribing across LHBs in
Wales was 69% (range 63–77%), compared with 74% in England.14
GP practices were given regular feedback on their data relative to
others and were also given a prescribing decision-support software
solution purchased by HBs in Wales to provide technological support
to help make generic prescribing easier in primary care. In 2004–5,
the NPI was also included in a national prescribing incentive scheme.
The generic prescribing rate increased year-on-year and, by 2008–9,
it had reached 85%.15 This released significant efficiencies within the
NHS Wales budget. If there is a demonstrable difference in clinical
TABLE 1 The “4E-s” of improvement strategies employed in Wales (2002–2020)
Driver Examples used in Wales
Education • Highlighting NICE guidelines and MHRA guidance
• Production and dissemination of AWMSG guidelines and resources
• Delivery of case-based learning workshops
• Annual best practice days
• Supporting implementation of recommendations in the Auditor General for Wales' report “Managing medicines in primary and
secondary care (2016)42
Economics • Financial incentives: e.g. Clinical Effectiveness Prescribing Programme (CEPP), NHS Wales outcome framework and measures, new
treatment Fund in Wales & Welsh Government's “Invest to save” schemes
• Removal of financial disincentives (e.g., removal by Welsh Government of prescription charges in 2007)
Engineering • Information via decision support systems
• “Server for prescribing information reporting and analysis” (SPIRA) dashboards (low value for prescribing, national prescribing
indicators, biosimilar efficiencies, medicine safety dashboard & national prescribing indicator reporting tool)
Enforcement • Highlighting MHRA guidance
• Highlighting UK legislative changes in medicines/prescribing
• Welsh Health Circulars (e.g., WHC/2003/73,20 WHC/2017/026)
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effect between each manufacturer's version of the formulation,
patients should always receive the same brand, and generic substitu-
tion is inappropriate. It was therefore also encouraging to note that
the level of another NPI, “inappropriate generic” prescribing fell from
15% as a percentage of items in an agreed drug basket (an agreed list
of medicines used as a comparator in relation to a specific indicator)
in 2002–3 to 2% by 2007–8, indicating marked concomitant improve-
ment in the appropriateness of prescribing over the same period that
generic prescribing had risen overall.15
After a 2010 report from the Bevan Commission and 1000 Lives
Plus, NHS Wales has sought to focus even more closely on reducing
inappropriate variation, as well as harm and waste.16 NPIs can be a
useful tool for comparative purposes, one example being the NPI for
tramadol. In 2012, the UK Advisory Committee on Misuse of Drugs
(ACMD) raised concerns that tramadol-related deaths were increasing
in England and Wales.17 They noted that data from the Office for
National Statistics (ONS) for 2011 showed 154 deaths where
tramadol had been mentioned on the death certificates, compared
with 83 such mentions in 2008. Most tramadol-related deaths were in
circumstances where it had been obtained through non-prescribed
means. However, prescribing of tramadol had increased in line with
the increase in deaths over the same period in both England and
Wales. AWMSG approved a tramadol prescribing NPI, and a national
survey, national audits and other educational resources were pro-
duced by a range of organisations in Wales in 2013–14. There was
subsequently a levelling off, then fall in the previously consistent rise
in prescribing, even before the reclassification of tramadol as a cate-
gory 3 medicine in the UK in June 2014.18 The tramadol NPI is still
active in Wales and a continuing decline in prescribing rates in Wales
towards levels closer to the rate in England up until March 2020 is
shown in Figure 2.
Other NPIs around medicines safety include the prescribing of
hypnotics and anxiolytics, opioid burden, prescribing of gabapentin
and pregabalin and rate of spontaneous reporting of suspected
adverse drug reactions via the UK Yellow Card scheme.19 Others
focus on antimicrobial stewardship. In 2018–19, some of the prescrib-
ing measures used in the “pharmacist-led information technology
intervention for medication errors” (PINCER) trial were also
adopted.19
3.2 | Prescribing committees and guidelines
When AWMSG was established in 2002, the structure of the existing
LHB prescribing committees in Wales was not uniform and their role
and influence were also variable. AWMSG therefore provided guid-
ance to the Welsh Government on the proposed future structure
and function of prescribing committees in Wales (WHC 2003/73).20
The main recommendations were aimed at ensuring that the new
LHB/Trust partnership Medicines and Therapeutics Committees
(MTCs) and AWMSG complemented each other's work and avoided
duplication. MTCs were asked to reach consensus, based on available
evidence, regarding the place in treatment of new medicines/
formulations or of existing medicines with new indications. They
would then ensure the advice was disseminated to stakeholder
organisations in a timely fashion. They were also judged best able to
advise on prescribing issues at the interface between primary and
secondary care (e.g., by agreeing shared-care guidelines), with
AWMSG advising on the rare occasions when national consensus
was difficult to achieve.
In 2002, there were also relatively few NICE guidelines so
AWMSG developed all-Wales guidelines in several areas where there
were challenging prescribing issues for which clear advice was deemed
necessary. These included advice on the safe and effective use of sta-
tins and antiplatelet agents (in 2004). AWMSG's aim has been to com-
plement and support the work of NICE and avoid duplication
wherever possible. As NICE produced more guidelines, these were
adopted in Wales and AWMSG then concentrated on developing
resources to complement them and support their implementation.
Over 60 AWMSG documents covering a wide range of medicines
optimisation issues are now available on the AWMSG website.
3.3 | Community prescribing resources
The Common Ailments Formulary was first approved by AWMSG in
2013 to support the Common Ailments Service (CAS) in the commu-
nity, initially in two pathfinder sites in Wales. It sought to provide
consistency of advice between GPs and pharmacists across Wales
and contained treatment options (with associated patient information
F IGURE 2 Trend in tramadol items dispensed
in Wales (quarters ending March 2014 to March
2020). Data Sources: NHS Wales Shared Services
Partnership's Comparative Analysis System for
Prescribing Audit (CASPA) and NHS Business
Services Authority, Electronic Prescribing Analysis
and Cost Tool (ePACT), 2020
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leaflets) for a range of minor health conditions. It supported commu-
nity pharmacists as they advised people on therapeutic options, many
of which could prevent an unnecessary GP visit. As a result of the
success of the pathfinder scheme, the second edition of the All-Wales
Common Ailments Formulary (covering 27 conditions) was approved
in 2018 and the scheme rolled out across every HB in Wales.21
AWMSG also worked in partnership with the Royal Pharmaceutical
Society (RPS) to produce an all-Wales version of the existing RPS
handbook to support the safe and effective delivery of homecare
services.22
3.4 | Patient safety resources
Medication errors can occur in hospital practice, and standardisation
of prescribing charts and processes is one important approach to
reducing them.23 In March 2004, AWMSG endorsed the introduc-
tion of a single harmonised standard in-patient medication adminis-
tration record across Wales. It was produced by a subgroup of the
Welsh Chief Pharmacists Committee and, after approval by
AWMSG, was rolled out across Wales in autumn of that year in con-
junction with agreed all-Wales Prescription Writing Standards and
an e-learning training package.24 In Australia, the introduction of a
single national chart was associated with a reduction of prescribing
errors of almost one-third.25 We believe that this initiative is one of
the most important ones supported by AWMSG, since all future
health professionals in training in Wales now learn to prescribe using
the same chart (a student version was developed for this purpose)
and will be familiar with it as they move between hospitals in Wales
during their training.
In 2015, AWMSG also approved an all-Wales syringe driver chart
for use in the community and secondary care. The All-Wales Policy for
Medicines Administration, Recording, Review, Storage and Disposal
(MARRS) was approved in 2015 and sets out the minimum standards
of practice that must be adopted by all healthcare employees involved
in the administration, recording, review, storage and disposal of medi-
cines in Welsh hospitals. A standardised All Wales Paediatric Steroid
Replacement Therapy Card to support the emergency treatment of
children with adrenal insufficiency was also approved in 2013.
High-risk medicines for which AWMSG has approved guidelines
include anticoagulants and opioids. AWMSG has also produced guid-
ance focusing on prescribing in the at-risk and frail older person and
the use of medicines in other high-risk situations. Other medicines
safety advice approved by AWMSG concerns safeguarding users of
opioid patches by standardising patient/caregiver counselling, the safe
use of proton pump inhibitors, guidance to support the safe use of
long-term oral bisphosphonate therapy, and materials to support
appropriate prescribing of hypnotics and anxiolytics across Wales.
Dosulepin is a tricyclic antidepressant that has been associated
with an increased risk of toxicity in overdose compared with some
other antidepressants. In the UK, the MHRA and NICE issued advice
on the prescribing of dosulepin, but these were not associated with
significant changes in the trend in dosulepin usage in Wales. In 2011,
AWMSG agreed an NPI to monitor usage and highlight the issues to
prescribers in Wales. The trend in dosulepin usage in Wales altered
significantly (downwards) following the introduction of the NPI. This
association, and the observation of no significant change in North-East
England over the same period, suggested that the NPI and associated
focus on the issue may have contributed to the effect seen.26
3.5 | Antimicrobial prescribing and stewardship
AWMSG first adopted an NPI measuring total volume of antibiotic
prescribing in 2014 to encourage the appropriate prescribing of all
antibiotics in primary care. To support health care practitioners to
address this issue, AWMSG approved 12 national audits linked to
a primary care prescribing incentive scheme, as part of the Therapeu-
tic Priorities and Clinical Effectiveness Prescribing Programme
in 2014–15. These were designed to promote antibiotic prescribing in
accordance with existing guidelines, and to support clinicians
in promoting quality improvement by reviewing antimicrobial pre-
scribing within their teams. Items (per 1000 specific therapeutic group
age-sex-related prescribing units [Star-PUs]) began to fall in 2015–16
for the first time and by 2019–20, the volume dispensed was 19%
lower than in 2014–15.19
3.6 | Prescribing efficiencies and optimisation
In 2018–19, prescribing expenditure in NHS Wales totalled £0.91
billion which represented 5.9% of total Welsh Government expendi-
ture.27 It is important that these resources are used wisely by ensuring
that clinically- and cost-effective medicines are available for prescrib-
ing in a timely fashion in Wales.
In 2009–10, the Welsh Government provided resources under its
“Invest to Save” scheme to support prescriber training in Wales to
reduce primary care prescribing costs in three main areas (proton
pump inhibitor, benzodiazepine and NSAID prescribing). An invest-
ment of around £600 000 over a three-year period was associated
with savings of £5.8 million in prescribing costs alone (an approximate
£10 saving per £1 of investment).28 We consider this to be one of the
most important milestones in medicines optimisation in Wales, since it
showed that a relatively modest investment in professional expertise
and data analytics could make a much greater impact on savings,
whilst at the same time, further promote rational and safe prescribing
by reducing overprescribing. Additionally, the Welsh Government
consequently agreed recurrent funding of the Welsh Analytical Pre-
scribing Support Unit (WAPSU) within AWTTC to work with AWMSG
in its goal of encouraging prudent and value-based prescribing.28
To ensure that prescribing of biological medicines is cost-
effective in primary and secondary care in Wales, an NPI measuring
the quantity of biosimilar medicines prescribed as a percentage of
total “reference” product plus biosimilar was adopted by AWMSG in
April 2016. HBs were provided with information (including a
PowerPoint slide presentation) for prescribers on why the NPI had
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been chosen and how implementation could occur. This was accompa-
nied by quarterly feedback on their prescribing relative to each other.
In 2017, biosimilars were part of a Best Practice Day where an early
adopting HB shared its experience. In addition, a dedicated national
Biosimilars Best Practice Day took place in January 2019 to further dis-
cuss strategies already shown to be effective in Wales and England.
The prescribing of biosimilars as a percentage of the total biological use
(i.e., “reference” product plus biosimilar) in Wales for four widely used
biologicals between 2016–17 and 2019–20 is shown in Figure 3.19
AWMSG has more recently approved advice relating to groups of
medicines which they considered “low priority for funding” (low value
for prescribing). The first group of medicines (agreed in 2017) included
five medicines; co-proxamol, doxazosin modified-release tablets, lido-
caine plasters, liothyronine and tadalafil once-daily preparations. In all
seven HBs in Wales, the spend for this bundle of medicines had fallen
in the financial year 2018–19 compared with 2016–2017.29,30 A fur-
ther four medicines; omega-3 fatty acid compounds, oxycodone and
naloxone combination product(s), paracetamol and tramadol combina-
tion product(s) and perindopril arginine, were added in 2018.
3.7 | Understanding the patient experience
Medicines optimisation must be inclusive, patient-focused and seek
insights from patients, their families and carers, patient organisations
and the public. Wales applies the principles of prudent healthcare to
inform its approach to delivery of health and social care. One of those
four principles highlights the need for “co-production”, an approach
built around people, where people and professionals share power and
work together in an equal partnership.31 AWMSG set up a Patient
and Public Interest Group (PAPIG), which held its first meeting in
October 2013. The group consists of patients, carers, representatives
from patient organisations and community health councils, and
members of the public. Meetings are held four times a year and are
well attended. Based on the group's discussions, a patient and public
engagement strategy was developed.
PAPIG members helped to develop the role and responsibilities of
lay members in AWMSG and AWPAG. Members regularly
contribute to AWMSG's work, by commenting on resources being
developed or out for consultation, or by proposing ideas for new ways
to improve information-sharing. PAPIG members also attend AWMSG
events, such as the annual Best Practice Day and Training Day. These
events often include presentations by patients and/or carers.
PAPIG members were involved in arranging AWMSG's first
Citizen's Jury, held over one week in July 2016, which focused on
the problem of antibiotic resistance. This event, facilitated by the
University of South Wales, allowed 14 members of the public to inter-
rogate the evidence around antimicrobial stewardship. The jury made
ten recommendations, which were sent to the Welsh Government
and formed the basis for a wider discussion about addressing antibi-
otic stewardship in Wales.32
During 2018–19, PAPIG supported two public health campaigns:
“Your Medicines Your Health” and “Making Choices Together”. Both
campaigns aimed to reduce medicines waste, in line with AWMSG's
2018 strategy. In 2019, collaboration was agreed with HealthWise
Wales to promote patient and public involvement. In one of the
projects, 1606 members of the public in Wales completed a question-
naire about their understanding of the UK Yellow Card scheme for
reporting suspected adverse drug reactions. Immediately after
watching a brief information video, 71% of the respondents reported
knowing how to report via the scheme compared with 18%
beforehand.33
Some further details of the AWMSG work programme and mile-
stones over the last 18 years are shown in a timeline (see Figure 4).
4 | DISCUSSION
Wales, like the other UK countries, continues to face significant health
challenges. It has a higher proportion of people aged over 60 years
than any of the other UK countries. The steady increase in life expec-
tancy seen since the Second World War began to stall around 2011.
F IGURE 3 Prescribing of biosimilar as a
percentage of the total biologic use
(i.e., “reference” product plus biosimilar)
2016–17 to 2019–20. Data source: NHS
Wales Shared Services Partnership,
Comparative Analysis System for Prescribing
Audit (CASPA), 2020
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For example, the all-cause mortality rate for Wales decreased by
almost 20% between 2002 and 2011, but there has been very little
change since 2011.34
There is a recognition in Wales that ready access to effective
medicines for all who could benefit from them is important in seeking
to achieve the best outcomes for patients. As a long-term investment
in health and to prevent the cost of prescriptions being a barrier to
access to care, the government in Wales gradually reduced (from
2004) and then, in 2007, abolished, all prescription charges8,35
Northern Ireland and Scotland also subsequently abolished charges.35
In Wales, the rise in number of prescription items dispensed per head
of population since 2007 has been broadly comparable with the
gradual rise that had been taking place prior to the abolition of
prescription charges in 2007.35,36
A New Treatment Fund providing an additional £16 million
annually for HBs and the trust in Wales to support the faster intro-
duction of new medicines deemed clinically- and cost-effective
(i.e., those approved by NICE or AWMSG) was introduced by the
Welsh Government in November 2017.37 Although HBs and the trust
had a 60-day deadline to make a newly recommended medicine avail-
able for prescription, by 2019 they were being made available in their
formularies in an average of 17 days.38
Although much has been achieved by coordination via AWMSG
of medicines optimisation initiatives in Wales since 2002, significant
challenges remain. The recently published data for 2019–20 based on
prescriptions dispensed in the community in Wales shows that the
number of items prescribed per person in Wales (26.0, including
prescriptions dispensed in the community) remains higher than in
England (19.9), Scotland (19.0) and Northern Ireland (22.5).36
However, the net ingredient cost (NIC) per head of population in
Wales (£188.39) was lower than in Scotland (£209.06) and Northern
Ireland (£229.79), but higher than England (£161.29). The NIC per
item prescribed was lower in Wales (£7.23) than in England (£8.11),
Northern Ireland (£10.23) and Scotland (£11.01).36
AWMSG has aligned its strategy going forward up to 2023 with
the principles of prudent healthcare,31 the aims of the Welsh
Government programmes of “Taking Wales Forward”39 and “Prosper-
ity for All: The National Strategy”40 and the recommendations in the
Parliamentary Review of Health and Social Care in Wales, “A Revolu-
tion from Within: Transforming Health and Care in Wales”.41 These
reports emphasise the importance of taking advantage of digital tech-
nologies to ensure better interconnectedness. The existing AWMSG
strategy was also informed by the report of the Auditor General for
Wales on managing medicines in primary and secondary care, which
highlighted the need to improve measurement of outcomes from the
use of medicines.42
In terms of the balance between HTA and medicines optimisation,
NICE has recently been conducting more HTAs of medicines, so
AWMSG/AWTTC are able to focus on medicines optimisation chal-
lenges to an even greater extent. Since March 2020, AWTTC staff
have also spent considerable time developing a repository of informa-
tion so that health care professionals in Wales can readily access
authoritative advice on the management of situations occurring during
the COVID-19 pandemic. The repository can be accessed on the
AWTTC website at www.awttc.org/covid-19.
In England, an operating model for Regional Medicines Optimi-
sation Committees (RMOCs) was published in 2017 and a second
version of the model was made available in 2020.43 RMOCs aim to
improve patient outcomes and ensure the NHS gets the best value
for the taxpayer through the provision of timely and credible advice
on medicines optimisation issues, for use and implementation by
local decision makers. They also aim to reduce local and regional
duplication and variation by identifying and addressing medicines
optimisation issues that would benefit from a coordinated
approach; and to promote awareness and support regional imple-
mentation of national policies and initiatives relating to medicines,
including supporting national guidance. These aims closely resemble
those of AWMSG, and over the last 18 years, AWMSG has shown
in Wales that they are realistic and achievable over a sustained
period.
There are presently four RMOCs (South, London, Midlands/East
and North) although it is hoped that seven will be established in due
course. AWMSG has always closely followed medicines optimisation
initiatives in England, Scotland and Northern Ireland and values any
opportunities for greater sharing of ideas and outcomes with the
RMOCs in England and similar groups in the other nations of the UK.
In 2016, the British Pharmacological Society (BPS) proposed that
a clinical pharmacologist should be a core member of the committee
structure of the proposed RMOCs in England and this is now the case.
A clinical pharmacologist has been a core member of AWMSG since it
F IGURE 4 Timeline showing selected activities of the All Wales Medicines Strategy Group between 2002 and 2020
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was established in 2002, and all the clinical pharmacologists in Wales
are involved either in AWMSG or its sub-committees, or in providing
professional support to AWMSG via AWTTC. Working collaboratively
with their pharmacist colleagues, they share their complementary
expertise. Professor Roger Walker, a former Chief Pharmaceutical
Officer for Wales observed that “By bringing their unique yet
complementary knowledge and skills to these collaborations, both
professions have made a much greater contribution to patient care
than either could have achieved by working alone”.44
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